With much of her wealth turning on Eli Lilly stock, which has had a topsy-turvy year (dropping from the mid-$80s to the mid-$40s, closing Friday at $61.30), one can make only broad estimates of values. Ewbank, citing his client's personal preference, did not engage in estimates, leaving them to the magazine.